



Name	CTS affiliation	Disclosure	Updated
Dell, Sharon	<ul style="list-style-type: none"> • Asthma • Pediatric Assembly 	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organisation that could lead to a real or perceived conflict of interest(s).</p> <p>Academic appointment(s) / employment: University: University of Toronto Hospital: The Hospital for Sick Children Research Funding: Peer-reviewed grants: National Institute of health (US), Ontario Lung Association, CIHR, Health Canada Industry-sponsored contracts: Parion Sciences Consultant/Advisor: Industry advisory board member: Vertex, Novartis Honoraria Speaker: AAP Celebration of Pediatric Pulmonology CME/Course development: ATS postgraduate course Volunteer/Board or Committee Member: Charitable Organization/Not for Profit: American Thoracic Society</p>	
Côté, Andréanne	<ul style="list-style-type: none"> • Asthma 		

Name	CTS affiliation	Disclosure	Updated
Francine M. Ducharme	<ul style="list-style-type: none"> • Co-Chair, Asthma CA • Pediatric Assembly 	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organisation that could lead to a real or perceived conflict of interest(s).</p> <ul style="list-style-type: none"> • Advisory board/consultation: Boehringer Ingelheim (2014-present) • Peer Review funding: CIHR: Canadian Founding for Innovation; Thrasler foundation, NCE • Research funding: CIHR: Canadian Founding for Innovation; Thrasler foundation, NCE • Research grant: CIHR: Canadian Founding for Innovation; Thrasler foundation, NCE, MSSS (Quebec) • Unrestricted grant: Novartis, Merck, Takeda, GSK, Trudell Medical, Boehringer Ingelheim • Academia: University of Montreal, McGill University • Employment: University of Montreal, CHU Sainte-Justine • Volunteer: ATS/ERS workgroup on preschooler wheezing; co-editor • Cochrane Airways Review Group • Advisor: RQAM (Quebec); INESSS (Quebec); Ontario Pediatric • Emergency Asthma Care Pathway (P EDACP) • Reviewer: for Granting agencies: FRQS, CIHR, ZonMW, Netherlands Asthma Foundation, Asthma UK Foundation, Israel Science Foundation, Children’s Hospital of Eastern Ontario Research Institute, Alberta Children’s Hospital Foundation, Alberta Heritage Foundation for Medical Research, Physicians’ Services Incorporated Foundation, Hospital for Sick Children Foundation, Children's Hospital of Eastern Ontario Research Institute; reviewer for numerous journals. • Lecturing/course development: CPASS (U of Montreal) • Speaker/honoraria: Merck Canada, Boehringer Ingelheim 	August 2017
Roland Grad	<ul style="list-style-type: none"> • 		

Name	CTS affiliation	Disclosure	Updated
Mark FitzGerald	<ul style="list-style-type: none">• Chair, Asthma CA• Long-term Planning Committee		

Name	CTS affiliation	Disclosure	Updated
Catherine Lemiere	<ul style="list-style-type: none"> • Asthma CA • CTS Board of Directors 	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p> <p>Academic appointment(s)/employment: University: Université de Montréal Hospital: CIUSSS du nord de l'île de Montréal-Hôpital du Sacré-Coeur de Montréal</p> <p>Research Funding : Peer-reviewed grants: Instituts de recherche en santé du Canada. Strategies to improve diagnosis and treatment of asthma in Canadians. Chercheur principal: Dr S. Aaron. Montant obtenu : 935 738 \$ (76 000 \$ prévu pour notre centre). 2011-2016.</p> <p>The Canadian Respiratory Research Network (CRRN) : Origin and progression of airway disease : 4,350,000\$: 2014-2019 Chercheur Principal Dr S Aaron 2013-2018</p> <p>Instituts de recherche en santé du Canada The EGFR; a key pathway in immune effector responses and asthmatic airway remodeling, Chercheur principal James G Martin Montant obtenu : 649 825\$ 2016-2021.</p> <p>Instituts de recherche en santé du Canada Impact of delayed asthma diagnosis during pregnancy on perinatal outcomes Chercheur principal : Lucie Blais Montant obtenu : 74, 920.00\$ 2017-2018</p> <p>Industry-sponsored contracts:</p> <p>Projets initiés par l'investigateur: Predictors of uncontrolled asthma: a real life study AstraZeneca (Investigator initiated study) Montant obtenu: 82 000\$. 2016-2018</p> <p>Assessment of airway inflammation and disease burden in moderate to severe asthmatic smokers. TEVA pharmaceuticals (investigator initiated Study) Montant obtenu : 122 000\$ 2016-2018</p>	July 2017

Name	CTS affiliation	Disclosure	Updated
Lemiere (cont'd)		<p>Étude de phase 3 d'une durée de 52 semaines, multicentrique, à double insu, contrôlée par placebo, avec répartition aléatoire et groupes parallèles, visant à évaluer l'efficacité et l'innocuité du tralokinumab chez des adolescents et des adultes dont l'asthme n'est pas bien maîtrisé avec un corticostéroïde par inhalation et un agoniste des récepteurs β_2 à longue durée d'action (D2210C00008) Commanditaire : AstraZeneca Chercheur principal : Lemiere C. Co-chercheur : Cartier A. Montant prévu au contrat 105,999\$ Février 2015-juin 2016</p> <p>Étude à répartition aléatoire, à double insu, contrôlée par placebo avec groupes parallèles, multicentrique d'une durée de 24 semaines, visant à évaluer l'efficacité et la sécurité du mépolizumab en ajout au traitement usuel pour l'asthme chez des sujets atteints d'asthme grave éosinophilique. Commanditaire GlaxoSmithKline Chercheur principal : Lemiere C. Co-chercheur : Cartier A. Mars 2015-mars 2016</p> <p>Étude de phase III, multicentrique, randomisée, à double insu avec groupes parallèles visant à évaluer l'efficacité et la sécurité de Symbicort[®] (budésonide / formotérol) Turbuhaler[®] 160/4.5 ug «au besoin» par rapport à terbutaline Turbuhaler[®] 0,4 mg « au besoin » et Pulmicort[®] (budésonide) Turbuhaler[®] 200 mg deux fois par jour ainsi que terbutaline Turbuhaler[®] 0,4 mg «au besoin» Commanditaire : AstraZeneca Chercheur principal : Lemiere C. Co-chercheur : Cartier A. Montant : 56430\$ Janvier 2015-janvier 2016</p> <p>Une étude à répartition aléatoire, à double insu, avec contrôle placebo et groupe parallèle pour évaluer l'efficacité et l'innocuité du dupilumab sur des patients souffrant d'asthme persistant. Chercheur principal : Lemiere C. Co-chercheur : Cartier A. Juin 2015 à septembre 2016 Commanditaire Sanofi Montant prévu: 100 000\$</p>	

Name	CTS affiliation	Disclosure	Updated
Lemiere (cont'd)		<p>Étude sur les coûts directs de la maladie chez les patients souffrant d'asthme modéré à sévère au Québec (Partie A) - Étude sur les coûts indirects de la maladie chez les patients souffrant d'asthme modéré à sévère au Québec (Partie B). Catherine Lemière, M.D., MSc et Lucie Blais, Ph. D., Montant 70 091.0\$ Commanditaire GlaxoSmithkline Novembre 2014-Novembre 2016</p> <p>Une étude multicentrique échelonnée sur 52 semaines, à répartition aléatoire, à double insu, avec contrôle placebo pour évaluer l'efficacité et la sécurité du QAW039 en ajout à la thérapie existante auprès des patients avec un asthme sévère inadéquatement contrôlé. Commanditaire Novartis Montant prévu 50 000\$ Juillet 2016- juillet 2017</p> <p>Étude de phase III randomisée en double aveugle à groupes parallèles comparant l'efficacité, la sécurité et la opérabilité d'une dose fixe de la combinaison FF/UMEC/VI à une dose fixe de la combinaison FF/VI administrée une fois par jour chez des sujets avec asthme inadéquatement contrôlé. Automne 2016 -2017.</p> <p>Consultant/Advisor: Industry advisory board member: AstraZeneca, GlaxoSmithKline, TEVA Government Agency: Other government body or committee: CNESST</p> <p>Honoraria: Speaker: AstraZeneca, TEVA CME/Course development: Development of educational material: TEVA, AstraZeneca</p> <p>As a member of the CTS Board of Directors are you: Related to a provincial or federal government employee or official (please specify): No</p>	

Name	CTS affiliation	Disclosure	Updated
Diane Lougheed	<ul style="list-style-type: none"> Asthma CA CTS Board of Directors 	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p> <p>Academic appointment(s)/employment: University: Queen' university Hospital: Kingston Health Sciences Centre (Kingston General Hospital, Hotel Dieu) and Providence Core Other: Institute for Clinical Evaluative Sciences Research funding:</p> <ul style="list-style-type: none"> Peer reviewed grants: Government of Ontario Innovation Fund (Southeastern Ontario Academic Health Sciences Alternate Funding Plan), Ontario Lung Association (Ontario Thoracic Society), Queen's University Industry-sponsored contracts: GlaxoSmithKline, Hoffman LaRoche, Janssen Other: Ontario Lung Association (subcontract from the Ontario Government, Ministry of Health's Asthma Program) <p>Consultant/Advisor: Government Agency - Health Canada: Public Service Occupational Health Program (NCR), Regions and Programs Bureau Honoraria CME/Course development: Development of educational material: Ontario Lung Association (Managing Severe Asthma) patient education booklet Volunteer/Board or Committee Member: Charitable Organization/Not for profit: CLA Governance Renewal Subcommittee</p> <p>As a member of the CTS Board of Directors are you: Related to a provincial or federal government employee or official (please specify): No</p>	July 2017
Ron Olivenstein	<ul style="list-style-type: none"> Asthma 		
Clare Ramsey	<ul style="list-style-type: none"> Asthma 		
Anne Van Dam	<ul style="list-style-type: none"> Staff 	Over the last two years, I have not had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.	October 2017
Cristina Villa-Roël	Appointed by the Canadian Association of Emergency Physicians.		
Wade Watson	<ul style="list-style-type: none"> Asthma CA 	Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.	

Name	CTS affiliation	Disclosure	Updated
Connie Yang	<ul style="list-style-type: none"> • Asthma CA • Pediatric Assembly 	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p> <p>Academia: University of British Columbia Employment University of British Columbia Hospital: BC Children’s Hospital Other: Child and Family Research Institute Consultant/Advisor: Industry advisory board member: Novartis Government Agency: Provincial Ministry of Health: British Columbia GPAC Guideline committee Honoraria: Speaker: UBC Respiratory Update, St. Paul’s CME Conference CME/Course development: Development of educational material: Child Health BC for provincial asthma guidelines</p>	March 2017